Adoptive transfer of metabolically reprogrammed macrophages for atherosclerosis treatment in diabetic ApoE−/- mice

Wang, Tingting; Dong, Yan; Yao, Li; Liu, Fan; Wen, Chenxi; Wan, Zhuo; Fan, Li; Li, Zhelong; Bu, Te; Wei, Mengying; Yang, Xuekang; Zhang, Yi

doi:10.1016/j.bioactmat.2022.02.002

Cited by 4 publications

(3 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the progressive understanding of atherosclerotic pathology, the current view holds that atherosclerosis has a complex immune inflammatory reaction, making immunotherapy possible. [ 242 ] Early acute inflammatory cells are enriched in plaque, attracted major contributors (mononuclear macrophages), and eventually macrophages interacted with neutrophils and T cells to maintain inflammation. Immunotherapy can regulate the intraplaque inflammatory microenvironment by cutting off or alleviating the cascade response of the inflammatory network.…”

Section: Therapymentioning

confidence: 99%

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Cheng,

Huang,

Chen

et al. 2023

Advanced Science

View full text Add to dashboard Cite

With the changing disease spectrum, atherosclerosis has become increasingly prevalent worldwide and the associated diseases have emerged as the leading cause of death. Due to their fascinating physical, chemical, and biological characteristics, nanomaterials are regarded as a promising tool to tackle enormous challenges in medicine. The emerging discipline of nanomedicine has filled a huge application gap in the atherosclerotic field, ushering a new generation of diagnosis and treatment strategies. Herein, based on the essential pathogenic contributors of atherogenesis, as well as the distinct composition/structural characteristics, synthesis strategies, and surface design of nanoplatforms, the three major application branches (nanodiagnosis, nanotherapy, and nanotheranostic) of nanomedicine in atherosclerosis are elaborated. Then, state‐of‐art studies containing a sequence of representative and significant achievements are summarized in detail with an emphasis on the intrinsic interaction/relationship between nanomedicines and atherosclerosis. Particularly, attention is paid to the biosafety of nanomedicines, which aims to pave the way for future clinical translation of this burgeoning field. Finally, this comprehensive review is concluded by proposing unresolved key scientific issues and sharing the vision and expectation for the future, fully elucidating the closed loop from atherogenesis to the application paradigm of nanomedicines for advancing the early achievement of clinical applications.

show abstract

Section: Therapymentioning

confidence: 99%

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Cheng,

Huang,

Chen

et al. 2023

Advanced Science

View full text Add to dashboard Cite

show abstract

“…During the formation and development of atherosclerotic plaques, macrophages are recruited and migrated into the arterial vessel wall [ 49 , 97 ]. Inspired by this aspect, macrophage membranes are frequently used to construct targeted delivery systems [ 47 , 80 , 98 ]. Zhou et al .…”

Section: Nature-inspired Nanocarriersmentioning

confidence: 99%

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

Ji,

Zhang,

Deng

et al. 2023

Regenerative Biomaterials

View full text Add to dashboard Cite

Atherosclerosis (AS) has emerged as one of the prevalent arterial vascular diseases characterized by plaque and inflammation, primarily causing disability and mortality globally. Drug therapy remains the main treatment for AS. However, a series of obstacles hinder effective drug delivery. Nature, from natural micro-/nano-structural biological particles like natural cells and extracellular vesicles to the distinctions between the normal and pathological microenvironment, offers compelling solutions for efficient drug delivery. Nature-inspired nanocarriers of synthetic stimulus-responsive materials and natural components, such as lipids, proteins, and membrane structures, have emerged as promising candidates for fulfilling drug delivery needs. These nanocarriers offer several advantages, including prolonged blood circulation, targeted plaque delivery, targeted specific cells delivery, and controlled drug release at the action site. In this review, we discuss the nature-inspired nanocarriers which leverage the natural properties of cells or the microenvironment to improve atherosclerotic drug therapy. Finally, we provide an overview of the challenges and opportunities of applying these innovative nature-inspired nanocarriers.

show abstract

“…In addition, macrophages have been associated with atherosclerotic plaque vulnerability [ 14 ]. Therefore, macrophages are important targets for atherosclerotic plaque detection and treatment [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Nobiletin alleviates atherosclerosis by inhibiting lipid uptake via the PPARG/CD36 pathway

Wang,

Tian,

Zhang

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

Background Atherosclerosis (AS) is a persistent inflammatory condition triggered and exacerbated by several factors including lipid accumulation, endothelial dysfunction and macrophages infiltration. Nobiletin (NOB) has been reported to alleviate atherosclerosis; however, the underlying mechanism remains incompletely understood. Methods This study involved comprehensive bioinformatic analysis, including multidatabase target prediction; GO and KEGG enrichment analyses for function and pathway exploration; DeepSite and AutoDock for drug binding site prediction; and CIBERSORT for immune cell involvement. In addition, target intervention was verified via cell scratch assays, oil red O staining, ELISA, flow cytometry, qRT‒PCR and Western blotting. In addition, by establishing a mouse model of AS, it was demonstrated that NOB attenuated lipid accumulation and the extent of atherosclerotic lesions. Results (1) Altogether, 141 potentially targetable genes were identified through which NOB could intervene in atherosclerosis. (2) Lipid and atherosclerosis, fluid shear stress and atherosclerosis may be the dominant pathways and potential mechanisms. (3) ALB, AKT1, CASP3 and 7 other genes were identified as the top 10 target genes. (4) Six genes, including PPARG, MMP9, SRC and 3 other genes, were related to the M0 fraction. (5) CD36 and PPARG were upregulated in atherosclerosis samples compared to the normal control. (6) By inhibiting lipid uptake in RAW264.7 cells, NOB prevents the formation of foam cell. (7) In RAW264.7 cells, the inhibitory effect of oxidized low-density lipoprotein on foam cells formation and lipid accumulation was closely associated with the PPARG signaling pathway. (8) In vivo validation showed that NOB significantly attenuated intra-arterial lipid accumulation and macrophage infiltration and reduced CD36 expression. Conclusions Nobiletin alleviates atherosclerosis by inhibiting lipid uptake via the PPARG/CD36 pathway.

show abstract

Adoptive transfer of metabolically reprogrammed macrophages for atherosclerosis treatment in diabetic ApoE−/- mice

Cited by 4 publications

References 72 publications

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Nanomedicine for Diagnosis and Treatment of Atherosclerosis

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

Nobiletin alleviates atherosclerosis by inhibiting lipid uptake via the PPARG/CD36 pathway

Contact Info

Product

Resources

About